[an error occurred while processing this directive] | [an error occurred while processing this directive]
Effect of KAT5/miR-210/TET2 pathway on radioresistance of anaplastic thyroid carcinoma
Cai Shang1, Xu Wenjing1, Wei Xi2, Xu Bo3, Tian Ye1
1Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China; 2Department of Ultrasound, Tumor Hospital of Tianjin Medical University, Tianjin 300060, China; 3Breast Cancer Research Centre, Tumor Hospital of Tianjin Medical University, Tianjin 300060, China
AbstractObjective To investigate the effect and mechanism of lysine acetyltransferase 5(KAT5) on the radio-sensitivity of anaplastic thyroid carcinoma (ATC). Methods The expression levels of endogenous KAT5 in ATC and normal thyroid cells were detected by Western blot and qRT-PCR. The effect of KAT5 specific inhibitor NU9056 on the radio-sensitivity of human ATC cells and normal thyroid cells was evaluated by colony formation assay. TCGA database, JASPAR database, along with Western blot, microRNA sequencing, qRT-PCR and dual-luciferase reporter assay were conducted to unravel the underlying mechanism. Results The expression of endogenous KAT5 at the protein and mRNA levels in human ATC cells was significantly higher than that in normal thyroid cells. NU9056 could significantly enhance the radiosensitivity of human ATC cells to 8505C and CAL-62, whereas showed no sensitization effect on normal thyroid cell Nthy-ori 3-1. Knockdown of KAT5 and NU9056 both down-regulated the expression level of miR-210 in the TC cells, while NU9056 decreased the expression level of transcription factor c-Myc. The putative binding sites of c-Myc in the miR-210 promoter region were predicted, and transfection of c-Myc plasmid significantly enhanced the luciferase activity of miR-210 promoter. Elevated miR-210 level was associated with worse survival of patients with thyroid carcinoma. Down-regulated expression of miR-210 decreased the TET2 mRNA level, while inhibition of miR-210 increased the TET2 mRNA level. Conclusion The aberrantly-activated KAT5/miR-210/TET2 pathway probably causes the radioresistance of ATC, becoming a novel sensitizing target for ATC radiotherapy in clinical practice.
Fund:National Natural Science Foundation Youth Project (81902715);Jiangsu Natural Science Foundation Youth Project (BK20180195);Suzhou Health and Family Planning Commission"Science and Education Xingwei" Youth Science and Technology Project (KJXW2017010);China Nuclear Power Group Kai Star Project (510003)
Corresponding Authors:
Tian Ye, Email:dryetian＠126.com
Cite this article:
Cai Shang,Xu Wenjing,Wei Xi et al. Effect of KAT5/miR-210/TET2 pathway on radioresistance of anaplastic thyroid carcinoma[J]. Chinese Journal of Radiation Oncology, 2021, 30(5): 503-508.
Cai Shang,Xu Wenjing,Wei Xi et al. Effect of KAT5/miR-210/TET2 pathway on radioresistance of anaplastic thyroid carcinoma[J]. Chinese Journal of Radiation Oncology, 2021, 30(5): 503-508.
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1):7-34. DOI:10.3322/caac.21551. [2] Lim H, Devesa SS, Sosa JA, et al. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013[J]. JAMA, 2017, 317(13):1338-1348. DOI:10.1001/jama.2017.2719. [3] Molinaro E, Romei C, Biagini A, et al. Anaplastic thyroid carcinoma:from clinicopathology to genetics and advanced therapies[J]. Nat Rev Endocrinol, 2017, 13(11):644-660. DOI:10.1038/nrendo.2017.76. [4] Liu TR, Xiao ZW, Xu HN, et al. Treatment and prognosis of anaplastic thyroid carcinoma:a clinical study of 50 cases[J]. PLoS One, 2016, 11(10):e0164840. DOI:10.1371/journal.pone.0164840. [5] Glaser SM, Mandish SF, Gill BS, et al. Anaplastic thyroid cancer:prognostic factors, patterns of care, and overall survival[J]. Head Neck, 2016, 38(Suppl 1):E2083-2090. DOI:10.1002/hed.24384. [6] Wendler J, Kroiss M, Gast K, et al. Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma:results of a multicenter study in Germany[J]. Eur J Endocrinol, 2016, 175(6):521-529. DOI:10.1530/EJE-16-0574. [7] Wei X, Cai S, Boohaker RJ, et al. KAT5 promotes invasion and metastasis through CMYC stabilization in ATC[J]. Endocr Relat Cancer, 2019, 26(1):141-151. DOI:10.1530/ERC-18-0193. [8] Zheng J, Zhang Y, Cai S, et al. MicroRNA-4651 targets bromodomain-containing protein 4 to inhibit non-small cell lung cancer cell progression[J]. Cancer Lett, 2020, 476:129-139. DOI:10.1016/j.canlet.2020.02.018. [9] Cai S, Shi GS, Cheng HY, et al. Exosomal miR-7 mediates bystander autophagy in lung after focal brain irradiation in mice[J]. Int J Biol Sci, 2017, 13(10):1287-1296. DOI:10.7150/ijbs.18890. [10] Narita T, Weinert BT, Choudhary C. Functions and mechanisms of non-histone protein acetylation[J]. Nat Rev Mol Cell Biol, 2019, 20(3):156-174. DOI:10.1038/s41580-018-0081-3. [11] Zhang J, Shen L, Sun LQ. The regulation of radiosensitivity by p53 and its acetylation[J]. Cancer Lett, 2015, 363(2):108-118. DOI:10.1016/j.canlet.2015.04.015. [12] Manickavinayaham S, Vélez-Cruz R, Biswas AK, et al. E2F1 acetylation directs p300/CBP-mediated histone acetylation at DNA double-strand breaks to facilitate repair[J]. Nat Commun, 2019, 10(1):4951. DOI:10.1038/s41467-019-12861-8. [13] Kaur S, Schwartz AL, Jordan DG, et al. Identification of schlafen-11 as a target of CD47 signaling that regulates sensitivity to ionizing radiation and topoisomerase inhibitors[J]. Front Oncol, 2019, 9:994. DOI:10.3389/fonc.2019.00994. [14] Lee HZ, Kwitkowski VE, Del Valle PL, et al. FDA approval:belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma[J]. Clin Cancer Res, 2015, 21(12):2666-2670. DOI:10.1158/1078-0432. CCR-14-3119. [15] Xie X, Xu Z, Wang C, et al. Tip60 is associated with resistance to X-ray irradiation in prostate cancer[J]. FEBS Open Bio, 2018, 8(2):271-278. DOI:10.1002/2211-5463.12371. [16] Laurberg JR, Brems-Eskildsen AS, Nordentoft I, et al. Expression of TIP60(tat-interactive protein) and MRE11(meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer[J]. BJU Int, 2012, 110(11 Pt C):E1228-1236. DOI:10.1111/j.1464-410X.2012.11564.x. [17] Rupaimoole R, Slack FJ. MicroRNA therapeutics:towards a new era for the management of cancer and other diseases[J]. Nat Rev Drug Discov, 2017, 16(3):203-222. DOI:10.1038/nrd.2016.246. [18] Griñán-LisónC, Olivares-Urbano MA, Jiménez G, et al. miRNAs as radio-response biomarkers for breast cancer stem cells[J]. Mol Oncol, 2020, 14(3):556-570. DOI:10.1002/1878-0261.12635. [19] Hu X, Peng Q, Zhu J, et al. Identification of miR-210 and combination biomarkers as useful agents in early screening non-small cell lung cancer[J]. Gene, 2020, 729:144225. DOI:10.1016/j.gene.2019.144225. [20] Wang D, Huang JH, Zeng QH, et al. Increased 5-hydroxymethylcytosine and ten-eleven translocation protein expression in ultraviolet b-irradiated hacat cells[J]. Chin Med J (Engl), 2017, 130(5):594-599. DOI:10.4103/0366-6999.200539. [21] Cadet J, Davies KJA, Medeiros MH, et al. Formation and repair of oxidatively generated damage in cellular DNA[J]. Free Radic Biol Med, 2017, 107:13-34. DOI:10.1016/j.freeradbiomed.2016.12.049.
2021, Vol. 30 
